Cognition Therapeutics
CGTX
27 hedge funds and large institutions have $4.59M invested in Cognition Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
35% more funds holding
Funds holding: 20 → 27 (+7)
1.51% more ownership
Funds ownership: 6.06% → 7.56% (+1.5%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
46% less capital invested
Capital invested by funds: $8.44M → $4.59M (-$3.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$676K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$553K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$294K |
| 4 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$193K |
| 5 |
DI
Diligent Investors
Redlands,
California
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$239K |
| 2 |
Millennium Management
New York
|
-$161K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$161K |
| 4 |
Two Sigma Investments
New York
|
-$159K |
| 5 |
Two Sigma Advisers
New York
|
-$157K |
CGTX Hedge Fund Activity: Q1 2022 in Review
27 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2022, worth a combined $4.59M — down 46% from $8.44M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CGTX positions and 4 closed out — a net gain of 7 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Worth Venture Partners, opening a new position worth an estimated $676K. The largest seller was Prosight Management, cutting an estimated $239K.
- 27 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $4.59M of Cognition Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
- 11 funds opened new Cognition Therapeutics positions in Q1 2022 and 4 closed out, a net change of +7 holders.
- The largest Cognition Therapeutics buyer in Q1 2022 was Worth Venture Partners, an estimated $676K added.
- The largest Cognition Therapeutics seller in Q1 2022 was Prosight Management, an estimated $239K sold.
Based on aggregated 13F filings for Q1 2022.